Rallybio (RLYB) EPS (Basic) (2020 - 2026)

Rallybio (RLYB) posted EPS (Basic) of -$1.46 for Q1 2026, down 39.98% sequentially from -$1.04 in Q4 2025, and up 7.99% YoY from -$1.35 in Q1 2025.

Rallybio (RLYB) EPS (Basic) (2020 - 2026) Analysis & Trends

Rallybio has reported EPS (Basic) for 7 years, with the latest figure at -$1.46 in Q1 2026.

Quarterly EPS (Basic) rose 7.99% year-over-year to -$1.46 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.32 (up 83.91% YoY) and the FY2025 annual result came in at -$1.44, up 85.89% from the prior year.
EPS (Basic) retreated to -$1.46 in Q1 2026 per RLYB's latest filing, from -$1.04 in the prior quarter.
Over five years, EPS (Basic) peaked at $2.84 in Q3 2025 and troughed at -$4.74 in Q3 2022.
A 5-year average of -$2.62 and a median of -$3.33 in 2023 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2025: EPS (Basic) plunged 65.36% in 2022, then jumped 246.37% in 2025.
Over 5 years, EPS (Basic) stood at -$4.02 in 2022, then increased by 3.42% to -$3.88 in 2023, then soared by 49.77% to -$1.95 in 2024, then surged by 46.69% to -$1.04 in 2025, then slumped by 39.98% to -$1.46 in 2026.
According to Business Quant data, EPS (Basic) over the past three periods registered -$1.46, -$1.04, and $2.84 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	12.62
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	7.59
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-1.96
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.23
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.06
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.18
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-0.72
10	Rallybio	95.20 Mn	95.20 Mn	-	7.66

Download Data